PRINCETON, N.J., June 14 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) announced today that it is scheduled to present at NASDAQ's
19th Investor Program Healthcare Forum on Tuesday, June 19, 2007 in London,
UK and on Wednesday, June 20, 2007 in Zurich, Switzerland. A live webcast
of the London presentation is scheduled for 9:15 AM Eastern Time (2:15 PM
BST) on June 19, 2007 and will be available for replay through the Webcasts
page in the Investor Relations section of the Medarex website via the
Internet at http://www.medarex.com .
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 30 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with six of the most advanced product candidates currently
in Phase III clinical trials. Medarex is committed to building value by
developing a diverse pipeline of antibody products to address the world's
unmet healthcare needs. For more information about Medarex, visit its
website at http://www.medarex.com .
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.
 back to top
Related links:
http://www.medarex.com
http://www.prnewswire.com/comp/108265.html /
CONTACT:
Laura S. Choi, Investor Relations,
+1-609-430-2880, Ext. 2216, or Jean Mantuano, Corporate
Communications (media), +1-609-430-2880, Ext. 2221, both of
Medarex, Inc.
|
